{"id":"NCT02673489","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection","officialTitle":"A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-15","primaryCompletion":"2017-03-02","completion":"2017-05-26","firstPosted":"2016-02-04","resultsPosted":"2018-03-29","lastUpdate":"2018-05-08"},"enrollment":106,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C"],"interventions":[{"type":"DRUG","name":"DCV","otherNames":[]},{"type":"DRUG","name":"SOF","otherNames":[]},{"type":"DRUG","name":"RBV","otherNames":[]}],"arms":[{"label":"Daclatasvir (DCV) + Sofosbuvir (SOF) + Ribavirin (RBV)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response (SVR12)","timeFrame":"Week 12","effectByArm":[{"arm":"HCV Treatment Naive","deltaMin":92.6,"sd":null},{"arm":"HCV Treatment Experienced","deltaMin":75,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":3},"locations":{"siteCount":19,"countries":["United States","Canada"]},"refs":{"pmids":["30382942"],"seeAlso":["http://bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":78},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Anaemia"]}}